171 related articles for article (PubMed ID: 22285105)
1. Estrogen activity as a preventive and therapeutic target in thyroid cancer.
Rajoria S; Suriano R; George AL; Shanmugam A; Jussim C; Shin EJ; Moscatello AL; Geliebter J; Carpi A; Tiwari RK
Biomed Pharmacother; 2012 Mar; 66(2):151-8. PubMed ID: 22285105
[TBL] [Abstract][Full Text] [Related]
2. Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions.
Kawabata W; Suzuki T; Moriya T; Fujimori K; Naganuma H; Inoue S; Kinouchi Y; Kameyama K; Takami H; Shimosegawa T; Sasano H
Mod Pathol; 2003 May; 16(5):437-44. PubMed ID: 12748250
[TBL] [Abstract][Full Text] [Related]
3. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression.
Tafani M; De Santis E; Coppola L; Perrone GA; Carnevale I; Russo A; Pucci B; Carpi A; Bizzarri M; Russo MA
Biomed Pharmacother; 2014 Feb; 68(1):1-5. PubMed ID: 24286852
[TBL] [Abstract][Full Text] [Related]
4. IQGAP1 modulates the proliferation and invasion of thyroid cancer cells in response to estrogen.
Meng D; Wu W; Li Z; Qin G
Int J Mol Med; 2015 Aug; 36(2):588-94. PubMed ID: 26046126
[TBL] [Abstract][Full Text] [Related]
5. A sorafenib-sparing effect in the treatment of thyroid carcinoma cells attained by co-treatment with a novel isoflavone derivative and 1,25 dihydroxyvitamin D3.
Izkhakov E; Sharon O; Knoll E; Aizic A; Fliss DM; Kohen F; Stern N; Somjen D
J Steroid Biochem Mol Biol; 2018 Sep; 182():81-86. PubMed ID: 29702263
[TBL] [Abstract][Full Text] [Related]
6. Disruption of 3D MCF-12A breast cell cultures by estrogens--an in vitro model for ER-mediated changes indicative of hormonal carcinogenesis.
Marchese S; Silva E
PLoS One; 2012; 7(10):e45767. PubMed ID: 23056216
[TBL] [Abstract][Full Text] [Related]
7. Anti-proliferative effects of a novel isoflavone derivative in medullary thyroid carcinoma: an in vitro study.
Greenman Y; Grafi-Cohen M; Sharon O; Knoll E; Kohen F; Stern N; Somjen D
J Steroid Biochem Mol Biol; 2012 Nov; 132(3-5):256-61. PubMed ID: 22776298
[TBL] [Abstract][Full Text] [Related]
8. Interlinking of hypoxia and estrogen in thyroid cancer progression.
Rajoria S; Hanly E; Nicolini A; George AL; Geliebter J; Shin EJ; Suriano R; Carpi A; Tiwari RK
Curr Med Chem; 2014; 21(11):1351-60. PubMed ID: 24304276
[TBL] [Abstract][Full Text] [Related]
9. Loss of estrogen receptor Beta expression in follicular thyroid carcinoma predicts poor outcome.
Heikkilä A; Hagström J; Mäenpää H; Louhimo J; Siironen P; Heiskanen I; Haglund C; Arola J
Thyroid; 2013 Apr; 23(4):456-65. PubMed ID: 23106428
[TBL] [Abstract][Full Text] [Related]
10. Estrogen induced metastatic modulators MMP-2 and MMP-9 are targets of 3,3'-diindolylmethane in thyroid cancer.
Rajoria S; Suriano R; George A; Shanmugam A; Schantz SP; Geliebter J; Tiwari RK
PLoS One; 2011 Jan; 6(1):e15879. PubMed ID: 21267453
[TBL] [Abstract][Full Text] [Related]
11. Estrogen and its role in thyroid cancer.
Derwahl M; Nicula D
Endocr Relat Cancer; 2014 Oct; 21(5):T273-83. PubMed ID: 25052473
[TBL] [Abstract][Full Text] [Related]
12. Metastatic phenotype is regulated by estrogen in thyroid cells.
Rajoria S; Suriano R; Shanmugam A; Wilson YL; Schantz SP; Geliebter J; Tiwari RK
Thyroid; 2010 Jan; 20(1):33-41. PubMed ID: 20067378
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-1280 modulates cell growth and invasion of thyroid carcinoma through targeting estrogen receptor α.
Meng D; Li Z; Ma X; Fu L; Qin G
Cell Mol Biol (Noisy-le-grand); 2016 Mar; 62(3):1-6. PubMed ID: 27064865
[TBL] [Abstract][Full Text] [Related]
14. Sex Bias in Differentiated Thyroid Cancer.
Suteau V; Munier M; Briet C; Rodien P
Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884794
[TBL] [Abstract][Full Text] [Related]
15. [Hormonal therapy in oncologic treatment: pathogenic hypotheses and interactions between thyroid and breast pathologies].
Parmeggiani D; Malinconico FA; Moccia G; Idà DN; Ripa C; Scala R; Foroni F; Gilio F; Cognetti C; Iside G; Agresti M
Tumori; 2003; 89(4 Suppl):215-9. PubMed ID: 12903598
[TBL] [Abstract][Full Text] [Related]
16. Reception of Sex Steroid Hormones in Thyroid Papillary Cancer Tissue and Relationship with Expression and Content of Transcription Factors Brn-3α and TRIM16.
Spirina LV; Chizhevskaya SY; Kondakova IV; Choinzonov EL
Bull Exp Biol Med; 2018 Dec; 166(2):237-240. PubMed ID: 30488195
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of estrogen receptors in thyroid lesions.
Vaiman M; Olevson Y; Habler L; Kessler A; Zehavi S; Sandbank J
Med Sci Monit; 2010 Jul; 16(7):BR203-7. PubMed ID: 20581768
[TBL] [Abstract][Full Text] [Related]
18. Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer.
Ho SM; Leung YK; Chung I
Ann N Y Acad Sci; 2006 Nov; 1089():177-93. PubMed ID: 17261766
[TBL] [Abstract][Full Text] [Related]
19. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in normal and malignant thyroid tissues by real-time polymerase chain reaction.
Egawa C; Miyoshi Y; Iwao K; Shiba E; Noguchi S
Oncology; 2001; 61(4):293-8. PubMed ID: 11721176
[TBL] [Abstract][Full Text] [Related]
20. Regulation of cell growth by estrogen signaling and potential targets in thyroid cancer.
Chen GG; Vlantis AC; Zeng Q; van Hasselt CA
Curr Cancer Drug Targets; 2008 Aug; 8(5):367-77. PubMed ID: 18690843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
